Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
SNDA vs DBVT vs ENSG vs ALKS vs NHC
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Medical - Care Facilities
Biotechnology
Medical - Care Facilities
SNDA vs DBVT vs ENSG vs ALKS vs NHC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Biotechnology | Medical - Care Facilities | Biotechnology | Medical - Care Facilities |
| Market Cap | $695M | $1712.35T | $10.18B | $5.90B | $2.66B |
| Revenue (TTM) | $381M | $0.00 | $5.27B | $1.56B | $1.50B |
| Net Income (TTM) | $-71M | $-168M | $363M | $153M | $101M |
| Gross Margin | -8.0% | — | 15.2% | 65.4% | 38.5% |
| Operating Margin | -15.3% | — | 8.5% | 12.3% | 8.1% |
| Forward P/E | — | — | 23.2x | 24.8x | 21.5x |
| Total Debt | $690M | $22M | $4.15B | $70M | $87M |
| Cash & Equiv. | $11M | $194M | $504M | $1.12B | — |
SNDA vs DBVT vs ENSG vs ALKS vs NHC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Sonida Senior Livin… (SNDA) | 100 | 369.5 | +269.5% |
| DBV Technologies S.… (DBVT) | 100 | 41.2 | -58.8% |
| The Ensign Group, I… (ENSG) | 100 | 398.7 | +298.7% |
| Alkermes plc (ALKS) | 100 | 216.4 | +116.4% |
| National HealthCare… (NHC) | 100 | 255.6 | +155.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SNDA vs DBVT vs ENSG vs ALKS vs NHC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SNDA ranks third and is worth considering specifically for growth.
- 25.2% revenue growth vs DBVT's -100.0%
DBVT is the clearest fit if your priority is momentum.
- +110.4% vs ALKS's +16.5%
ENSG has the current edge in this matchup, primarily because of its strength in growth exposure and long-term compounding.
- Rev growth 18.7%, EPS growth 14.1%, 3Y rev CAGR 18.7%
- 7.5% 10Y total return vs NHC's 198.2%
- Beta 0.42, yield 0.1%, current ratio 1.42x
- Beta 0.42 vs DBVT's 1.26
ALKS is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
- 9.8% margin vs SNDA's -18.7%
NHC is the #2 pick in this set and the best alternative if income & stability and valuation efficiency is your priority.
- Dividend streak 12 yrs, beta 0.60, yield 1.4%
- PEG 0.93 vs ENSG's 1.68
- Lower P/E (21.5x vs 23.2x), PEG 0.93 vs 1.68
- 1.4% yield, 12-year raise streak, vs ENSG's 0.1%, (2 stocks pay no dividend)
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 25.2% revenue growth vs DBVT's -100.0% | |
| Value | Lower P/E (21.5x vs 23.2x), PEG 0.93 vs 1.68 | |
| Quality / Margins | 9.8% margin vs SNDA's -18.7% | |
| Stability / Safety | Beta 0.42 vs DBVT's 1.26 | |
| Dividends | 1.4% yield, 12-year raise streak, vs ENSG's 0.1%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +110.4% vs ALKS's +16.5% | |
| Efficiency (ROA) | 6.8% ROA vs DBVT's -89.0% |
SNDA vs DBVT vs ENSG vs ALKS vs NHC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
SNDA vs DBVT vs ENSG vs ALKS vs NHC — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ALKS leads in 2 of 6 categories
NHC leads 2 • SNDA leads 0 • DBVT leads 0 • ENSG leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ALKS leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ENSG and DBVT operate at a comparable scale, with $5.3B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to SNDA's -18.7%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $381M | $0 | $5.3B | $1.6B | $1.5B |
| EBITDAEarnings before interest/tax | -$1M | -$112M | $558M | $212M | $166M |
| Net IncomeAfter-tax profit | -$71M | -$168M | $363M | $153M | $101M |
| Free Cash FlowCash after capex | -$9M | -$151M | $406M | $392M | $147M |
| Gross MarginGross profit ÷ Revenue | -8.0% | — | +15.2% | +65.4% | +38.5% |
| Operating MarginEBIT ÷ Revenue | -15.3% | — | +8.5% | +12.3% | +8.1% |
| Net MarginNet income ÷ Revenue | -18.7% | — | +6.9% | +9.8% | +6.7% |
| FCF MarginFCF ÷ Revenue | -2.3% | — | +7.7% | +25.1% | +9.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +6.2% | — | +18.4% | +28.2% | +12.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -3.5% | +91.5% | +21.9% | -4.1% | -8.4% |
Valuation Metrics
NHC leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 22.3x trailing earnings, NHC trades at a 25% valuation discount to ENSG's 29.8x P/E. Adjusting for growth (PEG ratio), NHC offers better value at 0.97x vs ENSG's 2.16x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $695M | $1712.35T | $10.2B | $5.9B | $2.7B |
| Enterprise ValueMkt cap + debt − cash | $1.4B | $1712.35T | $13.8B | $4.9B | $2.7B |
| Trailing P/EPrice ÷ TTM EPS | -8.67x | -0.76x | 29.85x | 24.76x | 22.35x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 23.19x | — | 21.51x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 2.16x | — | 0.97x |
| EV / EBITDAEnterprise value multiple | — | — | 25.71x | 17.25x | 15.85x |
| Price / SalesMarket cap ÷ Revenue | 1.82x | — | 2.01x | 4.00x | 1.81x |
| Price / BookPrice ÷ Book value/share | 11.76x | 0.66x | 4.59x | 3.28x | 2.50x |
| Price / FCFMarket cap ÷ FCF | — | — | 27.46x | 12.28x | 17.89x |
Profitability & Efficiency
ALKS leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
ENSG delivers a 16.6% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to SNDA's 12.26x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs NHC's 2/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -76.4% | -130.2% | +16.6% | +8.8% | +9.6% |
| ROA (TTM)Return on assets | -8.4% | -89.0% | +6.8% | +5.4% | +6.4% |
| ROICReturn on invested capital | -5.8% | — | +7.0% | +18.9% | +8.4% |
| ROCEReturn on capital employed | -7.7% | -145.7% | +10.2% | +14.2% | — |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 | 5 | 7 | 2 |
| Debt / EquityFinancial leverage | 12.26x | 0.13x | 1.86x | 0.04x | 0.08x |
| Net DebtTotal debt minus cash | $679M | -$172M | $3.7B | -$1.0B | $87M |
| Cash & Equiv.Liquid assets | $11M | $194M | $504M | $1.1B | — |
| Total DebtShort + long-term debt | $690M | $22M | $4.2B | $70M | $87M |
| Interest CoverageEBIT ÷ Interest expense | -0.86x | -189.82x | 88.33x | 32.30x | 24.41x |
Total Returns (Dividends Reinvested)
Evenly matched — SNDA and NHC each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NHC five years ago would be worth $26,213 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, DBVT leads with a +110.4% total return vs ALKS's +16.5%. The 3-year compound annual growth rate (CAGR) favors SNDA at 73.9% vs ALKS's 4.6% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +14.6% | +4.9% | +0.3% | +25.3% | +31.9% |
| 1-Year ReturnPast 12 months | +52.7% | +110.4% | +27.5% | +16.5% | +81.9% |
| 3-Year ReturnCumulative with dividends | +426.3% | +19.7% | +88.9% | +14.5% | +214.6% |
| 5-Year ReturnCumulative with dividends | -23.8% | -69.1% | +103.2% | +60.9% | +162.1% |
| 10-Year ReturnCumulative with dividends | -87.7% | -87.0% | +752.0% | -11.0% | +198.2% |
| CAGR (3Y)Annualised 3-year return | +73.9% | +6.2% | +23.6% | +4.6% | +46.5% |
Risk & Volatility
Evenly matched — ENSG and ALKS each lead in 1 of 2 comparable metrics.
Risk & Volatility
ENSG is the less volatile stock with a 0.42 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs DBVT's 76.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.10x | 1.26x | 0.42x | 1.06x | 0.60x |
| 52-Week HighHighest price in past year | $38.98 | $26.18 | $218.00 | $36.60 | $184.08 |
| 52-Week LowLowest price in past year | $23.53 | $7.53 | $133.81 | $25.17 | $93.54 |
| % of 52W HighCurrent price vs 52-week peak | +93.8% | +76.3% | +80.0% | +96.7% | +93.1% |
| RSI (14)Momentum oscillator 0–100 | 63.5 | 48.1 | 23.3 | 60.2 | 51.2 |
| Avg Volume (50D)Average daily shares traded | 602K | 252K | 358K | 2.3M | 117K |
Analyst Outlook
NHC leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: SNDA as "Hold", DBVT as "Buy", ENSG as "Buy", ALKS as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs -5.2% for SNDA (target: $35). For income investors, NHC offers the higher dividend yield at 1.44% vs ENSG's 0.14%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Buy | — |
| Price TargetConsensus 12-month target | $34.67 | $46.33 | $222.33 | $44.00 | — |
| # AnalystsCovering analysts | 3 | 15 | 13 | 28 | — |
| Dividend YieldAnnual dividend ÷ price | +0.9% | — | +0.1% | — | +1.4% |
| Dividend StreakConsecutive years of raises | 1 | 0 | 12 | 0 | 12 |
| Dividend / ShareAnnual DPS | $0.31 | — | $0.24 | — | $2.47 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.2% | +0.5% | +0.6% |
ALKS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). NHC leads in 2 (Valuation Metrics, Analyst Outlook). 2 tied.
SNDA vs DBVT vs ENSG vs ALKS vs NHC: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is SNDA or DBVT or ENSG or ALKS or NHC a better buy right now?
For growth investors, Sonida Senior Living, Inc.
(SNDA) is the stronger pick with 25. 2% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). National HealthCare Corporation (NHC) offers the better valuation at 22. 3x trailing P/E (21. 5x forward), making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SNDA or DBVT or ENSG or ALKS or NHC?
On trailing P/E, National HealthCare Corporation (NHC) is the cheapest at 22.
3x versus The Ensign Group, Inc. at 29. 8x. On forward P/E, National HealthCare Corporation is actually cheaper at 21. 5x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: National HealthCare Corporation wins at 0. 93x versus The Ensign Group, Inc. 's 1. 68x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — SNDA or DBVT or ENSG or ALKS or NHC?
Over the past 5 years, National HealthCare Corporation (NHC) delivered a total return of +162.
1%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: ENSG returned +752. 0% versus SNDA's -87. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SNDA or DBVT or ENSG or ALKS or NHC?
By beta (market sensitivity over 5 years), The Ensign Group, Inc.
(ENSG) is the lower-risk stock at 0. 42β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 198% more volatile than ENSG relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 12% for Sonida Senior Living, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — SNDA or DBVT or ENSG or ALKS or NHC?
By revenue growth (latest reported year), Sonida Senior Living, Inc.
(SNDA) is pulling ahead at 25. 2% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: National HealthCare Corporation grew EPS 17. 5% year-over-year, compared to -681. 5% for Sonida Senior Living, Inc.. Over a 3-year CAGR, ENSG leads at 18. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SNDA or DBVT or ENSG or ALKS or NHC?
Alkermes plc (ALKS) is the more profitable company, earning 16.
4% net margin versus -20. 0% for Sonida Senior Living, Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -15. 3% for SNDA. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SNDA or DBVT or ENSG or ALKS or NHC more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, National HealthCare Corporation (NHC) is the more undervalued stock at a PEG of 0. 93x versus The Ensign Group, Inc. 's 1. 68x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, National HealthCare Corporation (NHC) trades at 21. 5x forward P/E versus 23. 2x for The Ensign Group, Inc. — 1. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.
08Which pays a better dividend — SNDA or DBVT or ENSG or ALKS or NHC?
In this comparison, NHC (1.
4% yield), SNDA (0. 9% yield), ENSG (0. 1% yield) pay a dividend. DBVT, ALKS do not pay a meaningful dividend and should not be held primarily for income.
09Is SNDA or DBVT or ENSG or ALKS or NHC better for a retirement portfolio?
For long-horizon retirement investors, The Ensign Group, Inc.
(ENSG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 42), +752. 0% 10Y return). Both have compounded well over 10 years (ENSG: +752. 0%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SNDA and DBVT and ENSG and ALKS and NHC?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SNDA is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock; ENSG is a mid-cap high-growth stock; ALKS is a small-cap quality compounder stock; NHC is a small-cap quality compounder stock. SNDA, NHC pay a dividend while DBVT, ENSG, ALKS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.